Skip to main content
. 2010 Mar 12;15(3):246–252. doi: 10.1634/theoncologist.2009-0243

Figure 2.

Figure 2.

Efficacy of high-dose alkylating agents in patients with estrogen receptor–negative p53-mutated tumors.

Abbreviations: ddEC, dose-dense epirubicin and cyclophosphamide; E, single-agent epirubicin; FAC, 5-fluorouracil, doxorubicin, and cyclophosphamide; pCR, pathologic complete response.